Related Experiment Videos
Gene therapy for vein grafts.
1Cardiovascular Research Lab, Thorn 13, Brigham and Women's Hospital/Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Current Cardiology Reports
|September 12, 2000
Summary
Gene therapy offers a promising strategy to prevent bypass vein graft failure by manipulating vascular cell cycle progression. This approach redirects graft remodeling, reducing atherosclerosis and potentially improving outcomes for patients with myocardial and lower extremity ischemia.
Area of Science:
- Vascular Biology
- Gene Therapy
- Cardiovascular Surgery
Background:
- Bypass vein graft failure is a major challenge in treating myocardial and lower extremity ischemia.
- Understanding the molecular basis of neointimal hyperplasia and vein graft atherosclerosis is crucial for developing effective therapies.
Purpose of the Study:
- To explore gene-based therapies for preventing vein graft disease.
- To investigate the manipulation of vascular cell cycle regulation as a strategy to improve vein graft outcomes.
Main Methods:
- Investigated the genetic regulation of vascular cell cycle progression in vein grafts.
- Utilized experimental animal models to assess gene transfer strategies.
- Examined early clinical experiences with gene-based therapies.
Main Results:
- Manipulation of genetic regulation redirected vein graft biology from neointimal hyperplasia to medial hypertrophy.
- This approach effectively prevented experimental graft atherosclerosis.
- Early clinical data suggest potential for human translation.
Conclusions:
- Gene-based therapy targeting vascular cell cycle regulation is a viable strategy to prevent vein graft disease.
- This approach offers a promising avenue for improving surgical outcomes in patients with ischemic conditions.
- Vein grafts are well-suited for genetic manipulation due to direct access for intervention.